Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance

Author:

Pourmir IvanORCID,Elaidi Reza,Maaradji Zineb,de Saint Basile Hortense,Ung Monivann,Gazeau Benoit,Fournier Laure,Rance Bastien,Gibault Laure,Ismaili Mohammed,Fabre Elizabeth

Abstract

ABSTRACTAimsAnti-PD-1/PD-L1 can face the issue of tumor resistance in advanced non-small cell lung cancer (aNSCLC), mostly as primary resistance to the treatment. Still, disease progression (PD) also occurs after prior durable clinical benefit (DCB). Comparison of both situations and tools to evaluate residual benefit of PD-1/PD-L1 blockade are needed to understand and manage resistance.MethodsWe reviewed aNSCLCs with anti-PD-1/PD-L1 monotherapy, and disease progression per RECIST 1.1 (PD) in our center. Primary objective was comparison of post-progression survival (PPS) in primary resistance versus PD after DCB. Secondary objectives were to characterize patterns of PD after DCB; assess the feasibility and relevance of Tumor Growth Rate (TGR) in PD after DCB.Results148 patients were included. Median PPS were 5.2months (95% CI: 2.6-6.5) and 21.3months (95% CI: 18.5-36.3) (p<0.0001) for primary resistance and PD after DCB respectively. Multivariable hazard ratio for death in PD after DCB versus primary resistance was 0.14 (95% CI: 0.07-0.30). 76.7% of PD after DCB occurred in ≤3 lesions; 72.1% occurred only in preexisting lesions. TGR suggested a persistent benefit of PD-1/PD-L1 blockade in at least 44.2% of cases.ConclusionsPD after DCB was an independent factor of longer post-progression survival, with specific patterns of progression. TGR is a promising tool to assess residual benefit of immunotherapy.HighlightsAnti-PD-(L)1 immunotherapy still faces the problem of resistance in lung cancerResistance can be classified as primary or secondary (acquired)Outcomes and mechanisms of both situations need to be characterizedThis unique comparative study reveals diverging survival and progression patternsPrior durable clinical benefit associates with longer post-progression survivalThis data benefits our understanding and management of resistance to anti-PD-(L)1

Publisher

Cold Spring Harbor Laboratory

Reference39 articles.

1. The Global Cancer Observatory. Cancer fact sheet - All cancers. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf

2. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

5. Research C for DE and. Approved Drugs - Nivolumab (Opdivo). Accessed July 6, 2021. http://wayback.archive-it.org/7993/20170111231639/ http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htm

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3